Nuvation Bio Inc expected to post a loss of 11 cents a share - Earnings Preview

Nuvation Bio

30/10/2023 11:19

* Nuvation Bio Inc  NUVB.N   NUVB.K  is expected to show no
change
in quarterly revenue when it reports  results on November 1
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Nuvation Bio Inc is
for a
loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nuvation
Bio Inc
is $4.75​, above​ its last closing price of $1.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.11       -0.11      -0.09     Beat    19.5
 Mar. 31 2023  -0.10       -0.10      -0.10     Met     0
 Dec. 31 2022  -0.08       -0.11      -0.10     Beat    13​
 Sep. 30 2022  -0.14       -0.14      -0.12     Beat    14.3
 ​​Jun.        -0.13       -0.13      -0.16     Missed  -20.4
 30 2022                                                
 Mar. 31 2022  -0.14       -0.14      -0.10     Beat    30.6​
 Dec. 31 2021  -0.12       -0.12      -0.12     Met     -1.4
 Sep. 30 2021  -0.11       -0.11      -0.11     Met     -3.8
 This summary was machine generated October 30 at 11:19 GMT.  All
figures in US dollars  unless otherwise stated